Abu dhabi: Mubadala Bio has launched eight essential medicines in the UAE through its subsidiaries, marking a significant step in advancing national drug security and improving health outcomes.

According to Emirates News Agency, this initiative supports the UAE’s ambition to become a regional hub for life sciences, ensuring drug security, better access to essential medicines, and fostering a knowledge-based economy.

The new medicines, now locally produced at Mubadala Bio’s facilities including Gulf Inject, Wellpharma, and Bioventure Healthcare, cater to the growing demand for essential therapies. These products include Rivaroxaban, Linezolid, Sugammadex, Fluconazole, Pantoprazole, Ondansetron, Bupivacaine, and Sodium Chloride Inhalation Solution, which are pivotal for treating various medical conditions.

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, emphasized the company’s role in bolstering the UAE’s life sciences sector and ensuring a steady supply of critical medical therapies. Dr. Essam Mohamed, CEO of Mubadala Bio, highlighted the introduction of these medications as a demonstration of their commitment to local manufacturing and healthcare support.

Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, noted that these launches signify the company’s efforts to meet current healthcare needs while shaping the future of the life sciences industry. Mubadala Bio is positioned as a global leader, owning and operating 10 pharmaceutical assets worldwide and distributing over 10,000 products to more than 100 countries.